In a 77-year-old diabetic patient noncompliant with diet, currently on insulin aspart (Novolog) 35 U at breakfast, 30 U at lunch, and 30 U at dinner, and insulin glargine (Lantus) 45 U in the morning and 50 U at bedtime, with recent hemoglobin A1c of 7.8% and eGFR of 67 mL/min/1.73 m², and fasting and post‑prandial glucose values consistently elevated (fasting 173‑299 mg/dL, pre‑lunch 115‑300 mg/dL, pre‑dinner 148‑239 mg/dL, bedtime 122‑251 mg/dL), should the insulin regimen be adjusted?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, adjust the insulin regimen—this patient shows clear signs of overbasalization with excessive basal insulin doses and inadequate prandial coverage.

This 77-year-old patient is receiving 95 units of basal insulin daily (45 AM + 50 PM Lantus) while on 95 units of prandial insulin (35+30+30 Novolog), yet demonstrates persistent hyperglycemia throughout the day with an A1C of 7.8%. The current regimen reflects therapeutic inertia and overbasalization—a common pitfall where basal insulin is continuously increased without addressing postprandial excursions 1.

Key Problems with Current Regimen

The twice-daily Lantus dosing is inappropriate. Lantus (insulin glargine) is designed for once-daily administration with a 24-hour duration of action 2. Splitting it twice daily at these high doses (95 units total) suggests the provider has been chasing glucose targets by escalating basal insulin rather than optimizing the overall regimen—a classic sign of overbasalization 1, 3.

The glucose patterns reveal inadequate prandial insulin coverage despite high doses:

  • Morning glucose 173-299 mg/dL indicates insufficient overnight basal or dinner prandial coverage
  • Noon glucose 115-300 mg/dL shows breakfast prandial insulin is inadequate
  • Dinner glucose 148-239 mg/dL demonstrates lunch prandial coverage is insufficient
  • Bedtime glucose 122-251 mg/dL suggests dinner prandial insulin needs adjustment

Recommended Insulin Adjustment Strategy

Step 1: Consolidate and Reduce Basal Insulin

Convert to once-daily Lantus at 70-75 units in the morning 1, 4. When converting from twice-daily to once-daily basal insulin, use approximately 80% of the total current dose to reduce hypoglycemia risk 2. This gives 76 units (80% of 95 units), which can be rounded to 75 units given the persistent hyperglycemia.

The morning timing is preferred for older adults as it:

  • Reduces nocturnal hypoglycemia risk 4, 5
  • Allows better monitoring during waking hours
  • Simplifies the regimen for a noncompliant patient 6

Step 2: Optimize Prandial Insulin Dosing

Increase breakfast Novolog from 35 to 40 units to address the 173-299 mg/dL morning glucose values. The 2-unit increments every 3 days approach is too conservative given the degree of hyperglycemia 1.

Increase lunch Novolog from 30 to 35 units to target the noon glucose range of 115-300 mg/dL.

Increase dinner Novolog from 30 to 35 units to address the bedtime glucose of 122-251 mg/dL.

Step 3: Titration Protocol

Reassess in 1 week with focused glucose monitoring:

  • Fasting glucose should guide basal insulin adjustments (target 90-150 mg/dL for this age) 1, 4
  • Pre-lunch glucose guides breakfast prandial dose
  • Pre-dinner glucose guides lunch prandial dose
  • Bedtime glucose guides dinner prandial dose

Adjust by 2-4 units every 3-7 days based on glucose patterns 1. For hypoglycemia (glucose <80 mg/dL), reduce the corresponding insulin by 10-20% 1.

Critical Considerations for This Patient

Age and Renal Function

At 77 years with eGFR 67 mL/min/1.73m², this patient has Stage 2 CKD. Insulin clearance is reduced with declining renal function, increasing hypoglycemia risk 5, 4. The A1C target of <8% is appropriate for this older adult with moderate CKD and diet noncompliance 5, 4.

Diet Noncompliance

The documented diet noncompliance is likely the primary driver of glucose variability. However, rather than accepting poor control, the insulin regimen should be optimized to provide better coverage for the patient's actual eating patterns 7, 8. Consider:

  • Simplified carbohydrate counting education
  • Fixed meal timing if possible
  • Involvement of family/caregivers 4

Hypoglycemia Prevention

Prescribe glucagon for emergency hypoglycemia 1. Older adults have impaired counterregulatory responses and hypoglycemia unawareness 5, 4.

Educate on hypoglycemia recognition and treatment with 15-20g fast-acting carbohydrates 7.

Alternative Approach: Regimen Simplification

If the patient struggles with multiple daily injections, consider switching to twice-daily premixed insulin (70/30 or 75/25) 1, 4. This would provide:

  • Fewer injections (2 vs 4 daily)
  • Combined basal-prandial coverage
  • Simpler regimen for noncompliant patient

Start with 40 units before breakfast and 35 units before dinner, then titrate based on pre-lunch and bedtime glucose values 1, 4.

Monitoring Requirements

Increase glucose monitoring frequency temporarily to 4 times daily (fasting, pre-lunch, pre-dinner, bedtime) during titration 1, 9. Once stable, can reduce to fasting and one rotating time daily for older adults 4.

Reassess A1C in 3 months 1. The current A1C of 7.8% is acceptable for this patient's age and comorbidities, but the wide glucose excursions (173-300 mg/dL) indicate poor glycemic stability that increases complication risk 5, 4.

Common Pitfalls to Avoid

  • Do not continue escalating basal insulin beyond 0.5 units/kg/day without addressing prandial coverage 1, 3
  • Do not use Lantus twice daily—this negates its pharmacokinetic advantages 2
  • Do not set overly aggressive targets in older adults with hypoglycemia risk 5, 4
  • Do not ignore the diet noncompliance—address behavioral factors alongside medication adjustments 7, 8

Related Questions

What is the recommended insulin dosing for an adult with type 1 or type 2 diabetes?
For a patient with type 1 diabetes currently on insulin glargine (Lantus) 18 U daily, daytime insulin‑sensitivity factor of 25 mg/dL per unit, overnight factor of 50 mg/dL per unit, and insulin‑to‑carbohydrate ratio of 1 U per 8 g, who ate 56 g carbohydrate at 14:00 with a blood glucose of 200 mg/dL at 16:00, then ate 82 g carbohydrate at 19:00 with a blood glucose of 199 mg/dL at 22:00, and had a blood glucose of 132 mg/dL at 04:00, what should the insulin glargine dose, insulin‑sensitivity factor, and insulin‑to‑carbohydrate ratio be adjusted to?
In a 58-year-old patient with diabetes mellitus using insulin glargine (basal) and insulin aspart (prandial), what is the appropriate timing for each insulin dose?
What insulin dosing regimen and preferred basal and bolus insulin agents should be used for adults with type 1 diabetes mellitus, considering comorbid chronic conditions such as cardiovascular disease, chronic kidney disease, chronic liver disease, obesity, pregnancy, and elderly patients?
For a 59-year-old, 123‑kg man with type 2 diabetes (creatinine 0.84 mg/dL, eGFR > 90 mL/min) currently on U‑500 regular insulin (115 U at breakfast, 115 U at lunch, 50 U at dinner) and receiving dexamethasone 10 mg at 16:00 and 6 mg at 14:30, what NPH (intermediate‑acting) insulin dose should be added and how should the U‑500 insulin doses be adjusted?
What are the recommended dosage, administration schedule, onset, duration, contraindications, and adverse effects for proparacaine (Propericaine) ophthalmic anesthetic?
What is the recommended management and treatment plan for a patient with Alport syndrome?
What are the clinical indications for hyoscine (scopolamine)?
If a patient develops lichen planus while receiving Keytruda (pembrolizumab), should the drug be stopped and how should it be managed?
Is it good practice for a patient to alternate a full 20 mg dose of Seroxat (paroxetine) one day with a half‑dose (10 mg) the next day?
Is procaine an ester‑type local anesthetic?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.